JP2018509394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509394A5 JP2018509394A5 JP2017541594A JP2017541594A JP2018509394A5 JP 2018509394 A5 JP2018509394 A5 JP 2018509394A5 JP 2017541594 A JP2017541594 A JP 2017541594A JP 2017541594 A JP2017541594 A JP 2017541594A JP 2018509394 A5 JP2018509394 A5 JP 2018509394A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- dimer
- group
- terminus
- terminal extension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 239000000539 dimer Substances 0.000 claims 17
- 125000005647 linker group Chemical group 0.000 claims 16
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 210000004899 c-terminal region Anatomy 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- 238000002372 labelling Methods 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 8
- 239000003053 toxin Substances 0.000 claims 6
- 231100000765 toxin Toxicity 0.000 claims 6
- 108700012359 toxins Proteins 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 125000004450 alkenylene group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 230000001413 cellular effect Effects 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 3
- 229960003067 cystine Drugs 0.000 claims 3
- 125000000524 functional group Chemical group 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 102000004225 Cathepsin B Human genes 0.000 claims 2
- 108090000712 Cathepsin B Proteins 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000371 Esterases Proteins 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000003966 growth inhibitor Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000394 mitotic effect Effects 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 150000003573 thiols Chemical group 0.000 claims 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 229910001431 copper ion Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 239000002808 molecular sieve Substances 0.000 claims 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112218P | 2015-02-05 | 2015-02-05 | |
| US62/112,218 | 2015-02-05 | ||
| US201562269434P | 2015-12-18 | 2015-12-18 | |
| US62/269,434 | 2015-12-18 | ||
| PCT/EP2016/052578 WO2016124781A1 (en) | 2015-02-05 | 2016-02-05 | Nanobody dimers linked via c-terminally engineered cysteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509394A JP2018509394A (ja) | 2018-04-05 |
| JP2018509394A5 true JP2018509394A5 (enExample) | 2019-03-22 |
| JP6894375B2 JP6894375B2 (ja) | 2021-06-30 |
Family
ID=55315425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541594A Active JP6894375B2 (ja) | 2015-02-05 | 2016-02-05 | C末端で操作されたシステインを介して連結されたNanobodyダイマー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11021544B2 (enExample) |
| EP (1) | EP3262068A1 (enExample) |
| JP (1) | JP6894375B2 (enExample) |
| CN (1) | CN107667113B (enExample) |
| AU (2) | AU2016214317B2 (enExample) |
| CA (1) | CA2975810C (enExample) |
| HK (1) | HK1249528A1 (enExample) |
| WO (1) | WO2016124781A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2772348T3 (es) * | 2014-12-19 | 2020-07-07 | Ablynx Nv | Dímeros de Nanobody con uniones cisteína |
| KR20250011229A (ko) | 2017-06-02 | 2025-01-21 | 메르크 파텐트 게엠베하 | Adamts 결합성 면역글로불린 |
| CN108610415B (zh) * | 2018-05-15 | 2025-08-29 | 康元大工生物技术(大连)有限公司 | 一种抗体复合物的制备方法 |
| JP7603600B2 (ja) * | 2019-03-08 | 2024-12-20 | リンクシス ベスローテン フェンノートシャップ | 細胞増殖又は細胞分化に関与する受容体を標的にする内在化結合分子 |
| EP3792283A1 (en) * | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| CN111004328A (zh) * | 2019-12-11 | 2020-04-14 | 深圳市国创纳米抗体技术有限公司 | 一种用于双抗体夹心法检测癌胚抗原的纳米抗体组合 |
| GB201918230D0 (en) | 2019-12-11 | 2020-01-22 | Prec Therapeutics Ltd | Antibodies and their uses |
| CA3175873A1 (en) * | 2020-03-30 | 2021-10-07 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| EP4214235A1 (en) * | 2020-09-16 | 2023-07-26 | LinXis B.V. | Internalizing binding molecules |
| CN114957476A (zh) * | 2021-02-23 | 2022-08-30 | 复旦大学 | 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体 |
| CN113624898B (zh) * | 2021-08-23 | 2023-08-25 | 成都诺和晟泰生物科技有限公司 | 一种手性镇痛类多肽药物的纯化方法 |
| EP4463135A2 (en) * | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN114957478B (zh) * | 2022-05-30 | 2023-08-18 | 华南农业大学 | 一种抗肉桂酰胺类杀菌剂的纳米抗体及其应用 |
| WO2024238790A1 (en) | 2023-05-17 | 2024-11-21 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| WO2024243469A1 (en) * | 2023-05-23 | 2024-11-28 | The University Of Chicago | Delivery of dna binding and transcriptional regulation compositions |
| EP4556907A1 (en) | 2023-11-20 | 2025-05-21 | Miltenyi Biotec B.V. & Co. KG | Site-specific conjugation of single domain antibody fragments (vhh) using equilibrium transfer alkylation reagent (etac) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2492092A1 (en) * | 2002-06-28 | 2004-01-08 | Greg Winter | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US9701754B1 (en) * | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| US7958832B2 (en) * | 2008-08-29 | 2011-06-14 | Nike, Inc. | Awl for making an awl feature in material for apparel |
| DK2982690T3 (da) * | 2009-04-30 | 2021-04-12 | Ablynx Nv | Fremgangsmåde til fremstilling af domæne-antistoffer |
| US9150640B2 (en) * | 2009-07-10 | 2015-10-06 | Ablynx N.V. | Method for the production of variable domains |
| US8987417B2 (en) * | 2010-11-29 | 2015-03-24 | National Research Council Of Canada | Covalently dimerized bivalent binding agents |
| LT2771364T (lt) | 2011-10-27 | 2019-09-10 | Genmab A/S | Heterodimerinių baltymų gamyba |
| JP2015521615A (ja) * | 2012-06-19 | 2015-07-30 | ポリセリックス・リミテッド | 抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート |
| CN105814082A (zh) * | 2013-09-26 | 2016-07-27 | 埃博灵克斯股份有限公司 | 双特异性纳米抗体 |
| ES2772348T3 (es) * | 2014-12-19 | 2020-07-07 | Ablynx Nv | Dímeros de Nanobody con uniones cisteína |
-
2016
- 2016-02-05 JP JP2017541594A patent/JP6894375B2/ja active Active
- 2016-02-05 CN CN201680020654.8A patent/CN107667113B/zh active Active
- 2016-02-05 AU AU2016214317A patent/AU2016214317B2/en active Active
- 2016-02-05 HK HK18107995.0A patent/HK1249528A1/zh unknown
- 2016-02-05 CA CA2975810A patent/CA2975810C/en active Active
- 2016-02-05 EP EP16703532.8A patent/EP3262068A1/en not_active Withdrawn
- 2016-02-05 WO PCT/EP2016/052578 patent/WO2016124781A1/en not_active Ceased
- 2016-02-05 US US15/548,830 patent/US11021544B2/en active Active
-
2021
- 2021-12-22 AU AU2021290305A patent/AU2021290305B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509394A5 (enExample) | ||
| US20250161479A1 (en) | Transglutaminase conjugation method and linker | |
| CN112261954B (zh) | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 | |
| US10941145B2 (en) | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor | |
| CA2917544C (fr) | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie | |
| EP2968583B1 (en) | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme | |
| JP2018510864A (ja) | トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 | |
| EP3668869A1 (en) | 6-amino-7,9-dihydro-8h-purin-8-one derivatives as toll-like receptor 7 (tlr7) agonists as immunostimulants | |
| JP2020531466A (ja) | 免疫刺激物質トル様受容体7(tlr7)アゴニストとしての6−アミノ−7,9−ジヒドロ−8h−プリン−8−オン誘導体 | |
| JP2020531469A (ja) | 三環式基を有するトル様受容体7(tlr7)アゴニスト、そのコンジュゲート、ならびにそれらの方法および使用 | |
| JP2017537893A5 (enExample) | ||
| EP3102606A2 (en) | Antibody-drug conjugates and immunotoxins | |
| JP2020506685A5 (enExample) | ||
| KR101972012B1 (ko) | 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도 | |
| JP2018509908A5 (enExample) | ||
| EP3102244A2 (en) | Antibody-drug conjugates and immunotoxins | |
| JP2016539190A5 (enExample) | ||
| KR20210102334A (ko) | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 | |
| CA3222359A1 (en) | Conjugates of checkpoint inhibitors with il-2, and uses thereof | |
| KR102861586B1 (ko) | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 | |
| WO2019191630A1 (en) | Selective reduction of antibodies | |
| WO2020096775A1 (en) | Sulfatase-cleavable linkers for antibody-drug conjugates | |
| EA045916B1 (ru) | Антитело, содержащее глутаминсодержащее с-концевое удлинение легкой цепи, его конъюгаты, способы и пути применения |